Project Grant R41AG084384
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$506K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Louisville, KY 40202, USA
Similar Awards
This is a Project Grant award from the National Institute on Aging (NIA), part of the Department of Health and Human Services, under the Aging Research Federal Grant Program (CFDA 93.866). The $787,103 award to Vanderbilt University aims to develop a novel siRNA-lipid conjugate ("siRNA-EG18") to silence target genes in brain myeloid cells, including microglia and macrophages, as a potential treatment approach for Alzheimer's disease. The award will fund comprehensive gene and protein...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel Alzheimer's disease therapeutic using targeted nanoparticles. The $504,732 award to Aphios Corp, a minority-owned biotechnology company, will support two phases of research. In Phase I, the company will nanoencapsulate an anti-CCR5 drug in targeted and non-targeted nanoparticles, characterize the formulations, and evaluate their impact on in vitro models of brain...
This federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to develop an effective targeted delivery system for the bioactive curcuminoids curcumin and bisdemethoxycurcumin to treat Alzheimer's disease and other neuroinflammatory disorders. The $1,006,428 award, spanning September 2024 to August 2025, will support the optimization of folate-functionalized exosomal formulations for trans-spinal delivery of these curcuminoids to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $835,417 to the Icahn School of Medicine at Mount Sinai to develop novel lipid nanoparticle (LNP) formulations for efficient delivery of nucleic acid-based therapeutics to the brain to treat Alzheimer's disease (AD). The key objectives are to: 1) synthesize innovative blood-brain barrier (BBB)-crossing lipids and formulate a library of LNPs, 2) engineer siRNA and mRNA sequences to modulate...
The National Institute on Aging (NIA) awarded a $295,000 Project Grant under the Aging Research program (CFDA 93.866) to Florida International University (FIU). The 2-year award, effective from September 15, 2024 to August 31, 2026, aims to develop a novel biotherapeutic nanogel system to target key biomarkers of Alzheimer's disease (AD). The proposed nanogels are designed to enhance blood-brain barrier penetration, inhibit amyloid-beta aggregation, and mitigate oxidative stress and...
This $679,424 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports preclinical studies to evaluate the efficacy of a novel nanoligomer treatment for reducing neuroinflammation and protecting against cognitive decline in mouse models of brain aging and Alzheimer's disease. The research aims to determine the ideal application of the NF-kB/NLRP3-targeted nanoligomer treatment, whether for prevention during aging or treatment of pathology, and to...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This $500,000 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) will support Sxrna Technologies, Inc. in developing an organoid toolkit for Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD). The company aims to create a platform for identifying senescent cells in living tissue, which can provide insights into the aging process and enable high-throughput drug screening in complex 3D tissue models. Specifically, the grant will fund...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $949,062 to Somatoceutics LLC to develop a novel peptide-based nanoparticle drug delivery system to improve the penetration of therapeutics across the blood-brain barrier for the treatment of Alzheimer's disease and related dementias. The key objectives are to 1) optimize the assembly, drug-loading, and blood-brain barrier transcytosis of the SMC-101 nanotubes in vitro, and 2) evaluate the...